Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 21:20 | 2026-05-08 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $78.97 | 3,540 | $279,570 | 105,212 |
| 2026-05-13 00:30 | 2026-05-11 | GNLX | GENELUX Corp | Smalling Ralph | Officer | SELL | $2.98 | 270 | $804 | 67,803 |
| 2026-05-13 00:30 | 2026-05-11 | GNLX | GENELUX Corp | Zindrick Thomas | Officer | SELL | $2.94 | 2,798 | $8,226 | 532,051 |
| 2026-05-13 00:30 | 2026-05-11 | GNLX | GENELUX Corp | Cappello Joseph | Officer | SELL | $2.97 | 605 | $1,799 | 154,549 |
| 2026-05-13 00:30 | 2026-05-11 | GNLX | GENELUX Corp | Yu Yong | Officer | SELL | $2.97 | 605 | $1,798 | 149,706 |
| 2026-05-12 23:47 | 2026-05-08 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.69 | 407,574 | $280,207 | 1,171,175 |
| 2026-05-12 23:26 | 2026-05-11 | ZTS | Zoetis Inc. | MCCALLISTER MICHAEL B | Director | BUY | $77.76 | 3,000 | $233,273 | 24,524 |
| 2026-05-12 23:28 | 2026-05-12 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer | OPT+S | $100.12 | 75,000 | $7,509,000 | 523,478 |
| 2026-05-12 22:52 | 2026-05-08 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $45.89 | 75,000 | $3,441,960 | 1,273,095 |
| 2026-05-12 22:26 | 2026-05-08 | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | SELL | $0.69 | 565,167 | $390,700 | 406,282 |
| 2026-05-12 21:25 | 2026-05-11 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $573.03 | 10,000 | $5,730,317 | 18,876 |
| 2026-05-12 21:25 | 2026-05-11 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $573.10 | 9,500 | $5,444,418 | 40,513 |
| 2026-05-12 20:54 | 2026-05-08 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | OPT+S | $25.06 | 45,000 | $1,127,502 | 169,669 |
| 2026-05-12 20:01 | 2026-05-11 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $52.28 | 351 | $18,350 | 41,810 |
| 2026-05-11 20:05 | 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer | OPT+S | $24.12 | 18,606 | $448,818 | 423 |
| 2026-05-11 20:30 | 2026-05-08 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $564.95 | 9,500 | $5,367,044 | 40,513 |
| 2026-05-12 01:30 | 2026-05-07 | MPLT | MapLight Therapeutics, Inc. | Lillie James Woodruff | Officer | SELL | $28.28 | 721 | $20,390 | 242,729 |
| 2026-05-12 01:30 | 2026-05-07 | MPLT | MapLight Therapeutics, Inc. | Foff Erin Pennock | Officer | SELL | $28.54 | 4,438 | $126,640 | 346,059 |
| 2026-05-12 01:30 | 2026-05-07 | MPLT | MapLight Therapeutics, Inc. | Kroeger Christopher A. | Director, Officer | SELL | $28.47 | 68,491 | $1,949,637 | 1,512,329 |
| 2026-05-12 01:30 | 2026-05-11 | MPLT | MapLight Therapeutics, Inc. | Hanson Kristopher | Officer | SELL | $30.13 | 13,917 | $419,264 | 162,331 |
| 2026-05-12 00:25 | 2026-05-07 | PTGX | Protagonist Therapeutics, Inc | Giraudo Bryan | Director | OPT+S | $100.10 | 59,130 | $5,918,878 | 12,695 |
| 2026-05-12 00:05 | 2026-05-07 | CLRB | Cellectar Biosciences, Inc. | CARUSO JAMES V | Director, Officer | BUY | $2.88 | 8,680 | $24,998 | 20,318 |
| 2026-05-12 00:07 | 2026-05-07 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | Officer | BUY | $2.88 | 8,680 | $24,998 | 20,451 |
| 2026-05-11 23:48 | 2026-05-07 | RCKT | ROCKET PHARMACEUTICALS, INC. | Chaudhuri Sarbani | Officer | SELL | $3.84 | 17,650 | $67,741 | 267,510 |
| 2026-05-11 23:14 | 2026-05-07 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $45.62 | 292,952 | $13,364,060 | 2,671,822 |
| 2026-05-11 22:58 | 2026-05-07 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $45.62 | 292,952 | $13,364,060 | 2,671,822 |
| 2026-05-11 22:36 | 2026-05-11 | ABEO | ABEONA THERAPEUTICS INC. | Vasanthavada Madhav | Officer | SELL | $5.96 | 5,548 | $33,073 | 313,071 |
| 2026-05-11 21:07 | 2026-05-07 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% owner | SELL | $40.12 | 276,513 | $11,094,918 | 6,432,715 |
| 2026-05-11 21:15 | 2026-05-07 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $67.40 | 80,000 | $5,392,240 | 4,358,447 |
| 2026-05-11 21:00 | 2026-05-08 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Soteropoulos Paula | Director | OPT+S | $85.47 | 599 | $51,197 | 0 |
| 2026-05-11 21:01 | 2026-05-07 | BMRN | BIOMARIN PHARMACEUTICAL INC | Friberg Gregory R | Officer | SELL | $53.85 | 3,281 | $176,682 | 51,818 |
| 2026-05-11 20:16 | - | ZOMDF | Zomedica Corp. | POWERS JOHNNY D | Director | BUY | $0.11 | 500,000 | $56,400 | 3,925,000 |
| 2026-05-11 19:54 | 2026-05-08 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | SELL | $30.00 | 10,000 | $300,000 | 134,985 |
| 2026-05-11 20:01 | 2026-05-08 | MBX | MBX Biosciences, Inc. | Azoulay Salomon | Officer | OPT+S | $38.36 | 70,003 | $2,685,518 | 14,769 |
| 2026-05-11 20:03 | 2026-05-07 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $54.36 | 305 | $16,580 | 42,161 |
| 2026-05-11 11:36 | 2026-05-07 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $578.54 | 9,500 | $5,496,084 | 40,513 |
| 2026-05-11 11:37 | 2026-05-07 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $578.58 | 10,000 | $5,785,775 | 18,876 |
| 2026-05-09 01:31 | 2026-05-08 | SYRE | Spyre Therapeutics, Inc. | HENDERSON MICHAEL THOMAS | Director | SELL | $74.40 | 80,000 | $5,952,048 | 88,606 |
| 2026-05-08 20:45 | 2026-05-07 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $153.21 | 666 | $102,039 | 0 |
| 2026-05-08 20:15 | - | TSSI | Zomedica Corp. | HEATON LARRY C II | Director, Officer | BUY | $0.11 | 250,000 | $27,500 | 1,250,000 |
| 2026-05-08 20:00 | 2026-05-06 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Director, Officer | SELL | $29.54 | 607 | $17,931 | 727,667 |
| 2026-05-08 20:02 | 2026-05-06 | MBX | MBX Biosciences, Inc. | Azoulay Salomon | Officer | SELL | $29.54 | 231 | $6,824 | 14,769 |
| 2026-05-08 15:51 | 2026-05-06 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Director, Officer | SELL | $31.25 | 9,600 | $300,043 | 93,640 |
| 2026-05-07 20:10 | 2026-05-05 | AIMD | Ainos, Inc. | chiang yao-chung | Director | BUY | $1.70 | 129 | $219 | 829 |
| 2026-05-08 01:58 | 2026-05-05 | GYRE | GYRE THERAPEUTICS, INC. | Luo Ying | Director, Officer | SELL | $8.04 | 10,315 | $82,927 | 2,565,226 |
| 2026-05-07 23:34 | 2026-05-05 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $54.61 | 18,608 | $1,016,228 | 56,152 |
| 2026-05-07 22:19 | 2026-05-05 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $40.99 | 75,000 | $3,074,303 | 1,348,095 |
| 2026-05-07 22:22 | 2026-05-05 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.64 | 100,581 | $64,221 | 1,578,749 |
| 2026-05-07 20:30 | 2026-05-05 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $51.83 | 20,000 | $1,036,600 | 2,231 |
| 2026-05-07 20:30 | 2026-05-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $589.52 | 9,500 | $5,600,469 | 40,513 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.